CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
Risperidone +1 moredrug
Likely dose
Risperidone 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04201834
NCT04201834Phase 2Completed

Risperidone for the Treatment of Huntington's Disease Chorea

University of Rochester·interventional·Posted Dec 17, 2019·Updated Mar 21, 2025

In Brief

A Phase 2 clinical trial evaluating Risperidone and BioStamp nPoint device for Huntington Disease and Chorea. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the safety and benefit of risperidone for the treatment of chorea (involuntary movements) in Huntington's disease. Risperidone is commonly used in clinical practice to treat chorea, however, it has not been approved by the Food and Drug Administration (FDA) to treat chorea. This study will examine 1) whether the investigators see MRI changes with risperidone treatment and 2) whether sensors applied to the participants body can measure chorea and detect changes in chorea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 17, 2019
Enrollment StartAug 13, 2020
Primary CompletionDec 30, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 6.5 years ago

Interventions

Risperidonedrug

capsule or tablet, 0.5 mg

BioStamp nPoint devicedevice

MC10 has developed the BioStamp nPointTM, a FDA 510(k) cleared medical device. This multimodal, reusable and rechargeable biosensor uses flexible and stretchable electronics to enable unobtrusive wear on the body and monitoring in the home. The sensors have accelerometry, gyroscopy, and ECG/EMG capabilities. A docking station enables wireless recharging and data collection.